Cancer-testis antigens in gastric adenocarcinoma: Integration of differential expression, clinical associations, survival, and co-expression networks
Microbes & Immunity · 24.04.2026 · 3 (3) · 025510135
DOI: 10.36922/mi025510135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbes & Immunity, online erschienen am 24.04.2026. Verfasst von Jade Dias Valente und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Gastric adenocarcinoma (GAC) remains one of the deadliest malignancies worldwide, and the identification of molecular biomarkers is essential to improve prognostic stratification and guide therapeutic strategies. Cancer-testis antigens (CTAs) represent promising targets for immunotherapy, yet their expression landscape in GAC remains limited, especially when considering comprehensive and updated gene lists. In this study, we analyzed 389 samples, including tumor, peritumoral, metaplastic, and normal tissues, using RNA sequencing data to characterize the transcriptional profile of CTAs in GAC. We identified 104 CTAs differentially expressed among groups, with a predominance of upregulated genes in tumors compared with other tissues. The expression of several CTAs, such as MAGEA2, MAGEA3, MAGEA6, MAGEA12, CTCFL, IGF2BP1, and GAST, showed significant associations with clinically relevant variables, including tumor–node–metastasis staging, lymph node involvement, metastasis, histological subtype, and therapeutic management. Survival analysis revealed 17 CTA genes associated with overall survival, of which 14 correlated with poor prognosis, whereas PIK3R3, SYCE1L, and ZNF683 demonstrated a protective effect. Co-expression analysis identified five well-defined functional modules, reflecting coordinated CTA signatures related to germline reprogramming, proliferation, and immune remodeling within the tumor microenvironment. Collectively, our results provide the most comprehensive characterization of CTAs in GAC to date, highlighting genes with clinical relevance, prognostic value, and translational potential as candidates for future personalized immunotherapeutic approaches.
Zitieren
APA
Valente, J. D., Marques, L. É. C., Mourão, R. M. D. S., Rodrigues, B. D. F. D. R., Souza, L. S. D., Silva, J. M. C. D., Casseb, S. M. M., Khayat, A. S., Demachki, S., Ishak, G., Moreira, F. C., Burbano, R. M. R., & Assumpção, P. P. D. (2026). Cancer-testis antigens in gastric adenocarcinoma: Integration of differential expression, clinical associations, survival, and co-expression networks. Microbes & Immunity, 3(3), 025510135. https://doi.org/10.36922/mi025510135
Vancouver
Valente JD, Marques LÉC, Mourão RMDS, Rodrigues BDFDR, Souza LSD, Silva JMCD, et al. Cancer-testis antigens in gastric adenocarcinoma: Integration of differential expression, clinical associations, survival, and co-expression networks. Microbes & Immunity. 2026;3(3):025510135. doi:10.36922/mi025510135
BibTeX
@article{Valente2026,
author = {Valente, Jade Dias and Marques, Livia Érika Carlos and Mourão, Ronald Matheus da Silva and Rodrigues, Bianca de Fátima dos Reis and Souza, Louise Sousa de and Silva, Jéssica Manoelli Costa da and Casseb, Samir Mansour Moraes and Khayat, André Salim and Demachki, Samia and Ishak, Geraldo and Moreira, Fabiano Cordeiro and Burbano, Rommel Mario Rodríguez and Assumpção, Paulo Pimentel de},
title = {Cancer-testis antigens in gastric adenocarcinoma: Integration of differential expression, clinical associations, survival, and co-expression networks},
journal = {Microbes & Immunity},
year = {2026},
volume = {3},
number = {3},
pages = {025510135},
doi = {10.36922/mi025510135}
}
EUVIMED